ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BAFF CAR-T

Its studies are mostly in Lymphoma, B-Cell, led by Luminary Therapeutics.

Furthest: phase 2, since Aug 11, 20261 company-led study, 1 open or runningNext primary completion: Dec 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Luminary Therapeutics11 open or runningphase 2since Aug 11, 2026Aug 11, 2026Dec 2030phase 2 · NCT07771361

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2026First study: phase 2 study in Lymphoma, Non-HodgkinFirst studyNCT07771361 · 90 planned

Ahead

  1. Dec 2030Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT07771361

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07771361Lymphoma, Non-Hodgkin2Not yet recruitingDec 203090

How it is read

Names in the registry

  • “BAFF CAR-T”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.